secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0001437749-26-013989
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex granted Israel patent for Reqorsa gene therapy with PD-1 antibodies
---------------------------------------------------------------------------

- Israel Patent Office granted patent covering Reqorsa (quaratusugene ozeplasmid) in combination with PD-1 antibodies for cancer treatment.
- Patent expands IP portfolio previously granted in U.S., Japan, Mexico, Russia, Australia, Chile, China, Singapore, and Europe.
- Reqorsa is initially being developed for lung cancer; preclinical data shows complementarity with targeted drugs and immunotherapies.
- Israel lung cancer cases rose 33% in a decade; 200 new cases/month; leading cancer death cause in 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774926013989/0001437749-26-013989-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774926013989/gnpx20260429_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-013989

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer